3-甲胺基吖丁啶 | 247069-31-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 3-甲胺基吖丁啶
• 中文别名: N-甲基氮杂环丁烷-3-胺盐酸盐；N-甲基-3-氮杂啶胺
• 英文名称: N-methylazetidin-3-amine
• CAS: 247069-31-4
• 化学式: C₄H₁₀N₂
• 分子量: 86.1368
• InChiKey: NQPTWMKTGPWPMX-UHFFFAOYSA-N

物化性质

• 熔点：
  121 - 123°C
• 沸点：
  120.5±8.0 °C(Predicted)
• 密度：
  0.93±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO（轻微，超声处理），甲醇（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-甲胺基吖丁啶 、 voreloxin中间体 以 乙腈 为溶剂， 生成 7-(3-Methylamino-azetidin-1-yl)-4-oxo-1-thiazol-2-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 2

  摘要：

  We have previously reported that a series of 7-substituted 6-fluoro-1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids possess moderate cytotoxic activity. In a further attempt to find clinically useful antitumor agents, we investigated the structure-activity relationships (SARs) of a new series of compounds obtained by changing the C-6 position of the fluorine atom in addition to the C-5 and C-7 positions and evaluating their cytotoxic activity against several murine and human tumor cell lines. Our results showed that the 6-unsubstituted 1,8-naphthyridine structure had the most potent cytotoxic activity against murine P388 leukemia twice that of the 6-fluoro analogue. In addition, introduction of an amino group at the C-5 position did not have any substantial effect on the cytotoxic activity, while both the 5-chloro and 5-trifluoromethyl groups decreased the cytotoxic activity by 5- to 10-fold. Moreover, aminopyrrolidine derivatives at the C-7 position showed more potent cytotoxic activity than other amines or carbon derivatives. Among the 7-(3-aminopyrrolidinyl) derivatives, the trans-3-methoxy-4-methylaminopyrrolidinyI derivative (271) was determined to have potent cytotoxic activity in both in vitro and in vivo assays and high water solubility. Finally, the (SS)-isomer (AG-7352, 3) of 271, with a cytotoxic activity against human tumor cell lines more potent than that of etoposide, was selected for further development.

  DOI：

  10.1021/jm0304966
• 作为产物：
  描述：

  Tert-butyl 3-[methyl(prop-2-en-1-yl)amino]azetidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-甲胺基吖丁啶
  参考文献：
  名称：

  [EN] PROTEIN REGULATOR-TARGETED COMPOUND AND APPLICATION THEREOF
  [FR] COMPOSÉ CIBLANT UN RÉGULATEUR DE PROTÉINE ET SON APPLICATION
  [ZH] 一种靶向蛋白调节剂的化合物及其应用

  摘要：

  一种靶向蛋白调节剂的化合物及其应用。该化合物为如式Ia、Ib或Ic所示的化合物。该化合物对KRAS_G12D突变体具有良好的抑制作用和蛋白降解作用。

  公开号：

  WO2022228576A1

文献信息

• SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS
  申请人：BIGNAN Gilles

  公开号：US20110150864A1

  公开（公告）日：2011-06-23

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式（I）化合物、制备这些化合物的方法、组合物、中间体和衍生物，以及用于治疗包括但不限于强直性脊柱炎、动脉粥样硬化、关节炎（如类风湿性关节炎、感染性关节炎、儿童关节炎、银屑病性关节炎、反应性关节炎）、与骨相关的疾病（包括与骨形成有关的疾病）、乳腺癌（包括对抗雌激素治疗无效的乳腺癌）、心血管疾病、软骨相关疾病（如软骨损伤/丧失、软骨退化以及与软骨形成有关的疾病）、软骨发育不良、软骨肉瘤、慢性背部损伤、慢性支气管炎、慢性炎性气道疾病、慢性阻塞性肺疾病、糖尿病、能量稳态紊乱疾病、痛风、假性痛风、脂质代谢紊乱、代谢综合征、多发性骨髓瘤、肥胖症、骨关节炎、成骨不全症、骨转移性溶骨性肿瘤、软骨软化症、骨质疏松症、帕吉特病、牙周病、多肌病性风湿病、Reiter综合症、重复性应力损伤、高血糖、血糖水平升高和胰岛素抵抗等疾病的治疗。
• Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US08263781B2

  公开（公告）日：2012-09-11

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及化合物(I)的配方、制备这些化合物的方法、组合物、中间体和衍生物，以及用于治疗包括但不限于强直性脊柱炎、动脉粥样硬化、关节炎（如类风湿性关节炎、感染性关节炎、儿童关节炎、银屑病性关节炎、反应性关节炎）、与骨相关的疾病（包括与骨形成有关的疾病）、乳腺癌（包括对抗雌激素治疗无效的乳腺癌）、心血管疾病、软骨相关疾病（如软骨损伤/丢失、软骨退化和与软骨形成有关的疾病）、软骨发育不良、软骨肉瘤、慢性背部损伤、慢性支气管炎、慢性炎性气道疾病、慢性阻塞性肺疾病、糖尿病、能量稳态失调疾病、痛风、假性痛风、脂质代谢异常、代谢综合征、多发性骨髓瘤、肥胖症、骨关节炎、成骨不全症、骨溶解性骨转移、软骨软化症、骨质疏松症、佩吉特病、牙周病、多肌病性风湿病、Reiter综合征、重复性应力损伤、高血糖、血糖升高和胰岛素抵抗等疾病的治疗。
• A Novel Antibacterial 8-Chloroquinolone with a Distorted Orientation of the N1-(5-Amino-2,4-difluorophenyl) Group
  作者：Yasuhiro Kuramoto、Yoshihiro Ohshita、Jiro Yoshida、Akira Yazaki、Motoo Shiro、Tohru Koike

  DOI：10.1021/jm0205090

  日期：2003.5.1

  Fluoroquinolones represent a major class of antibacterial agents with great therapeutic potential. In this study, we designed m-aminophenyl groups as novel N-1 substituents of naphthyridones and quinolones. Among newly synthesized compounds, 7-(3-aminoazetidin-1-yl)-1-(5-amino-2,4-difluorophenyl)-8-chloro-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4) has extremely potent antibacterial activities against Gram (+) as well as Gram (-) bacteria. This compound is significantly more potent than trovafloxacin against clinical isolates: 30 times against Streptococcus pneumoniae and 128 times against methicillin resistant Staphylococcus aureus. The structure-activity relationship (SAR) study revealed that a limited combination of 1-(5-amino-2,4-difluorophenyl) group, 7-(azetidin-1-yl) group, and 8-Cl atom (or Br atom or Me group) gave potent antibacterial activity. An X-ray crystallographic study of a 7-(3-ethylaminoazetidin-1-yl)-8-chloro derivative demonstrated that the N-1 aromatic group was remarkably distorted out of the core quinolone plane by steric repulsion between the C-8 C1 atom and the N-1 substituent. Furthermore, a molecular modeling study of 4 and its analogues demonstrated that a highly distorted orientation was induced by a steric hindrance of the C-8 substituent, such as Cl, Br, or a methyl group. Thus, their highly strained conformation should be a key factor for the potent antibacterial activity.